» Articles » PMID: 23027969

Aberrant Expression of C-Jun in Glioblastoma by Internal Ribosome Entry Site (IRES)-mediated Translational Activation

Overview
Specialty Science
Date 2012 Oct 3
PMID 23027969
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Although the protooncogene c-Jun plays a critical role in cell proliferation, cell death, and malignant transformation, DNA microarray screens have identified only a few human cancer types with aberrant expression of c-Jun. Here, we show that c-Jun accumulation is robustly elevated in human glioblastoma and that this increase contributes to the malignant properties of the cells. Most importantly, the increase in c-Jun protein accumulation occurs with no corresponding increase in c-Jun mRNA or the half-life of the c-Jun protein but, rather, in the translatability of the transcript. The c-Jun 5'UTR harbors a potent internal ribosomal entry site (IRES) with a virus-like IRES domain that directs cap-independent translation in glioblastoma cells. Accumulation of c-Jun is not dependent on MAPK activity but can be stimulated by a cytoskeleton-dependent pathway. Our findings provide evidence that human c-Jun is an IRES-containing cellular transcript that contributes to cancer development through translational activation. This previously undescribed mechanism of c-Jun regulation might also be relevant to other types of human cancer and offers unique potential targets for therapy.

Citing Articles

Optimized circular RNA vaccines for superior cancer immunotherapy.

Yu H, Wen Y, Yu W, Lu L, Yang Y, Liu C Theranostics. 2025; 15(4):1420-1438.

PMID: 39816687 PMC: 11729565. DOI: 10.7150/thno.104698.


DDX50 cooperates with STAU1 to effect stabilization of pro-differentiation RNAs.

Miao W, Porter D, Siprashvili Z, Ferguson I, Ducoli L, Nguyen D Cell Rep. 2025; 44(1):115174.

PMID: 39764852 PMC: 11875220. DOI: 10.1016/j.celrep.2024.115174.


Unveiling the link between arsenic toxicity and diabetes: an in silico exploration into the role of transcription factors.

Fatema K, Haidar Z, Tanim M, Nath S, Sajib A Toxicol Res. 2024; 40(4):653-672.

PMID: 39345741 PMC: 11436564. DOI: 10.1007/s43188-024-00255-y.


Inhibition of circular JUN prevents the proliferation and invasion of glioblastoma via miR-3064-IGFBP5 axis.

Zhang Y, Liu S, Wu C, Gao X, Zhao H, Li O J Cell Mol Med. 2024; 28(18):e70098.

PMID: 39307884 PMC: 11416905. DOI: 10.1111/jcmm.70098.


eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

Boyer J, Sharma M, Dorso M, Mai N, Amor C, Reiter J bioRxiv. 2024; .

PMID: 38766126 PMC: 11100762. DOI: 10.1101/2024.05.08.593195.


References
1.
Spangler B, Kappelmann M, Schittek B, Meierjohann S, Vardimon L, Bosserhoff A . ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma. Int J Cancer. 2011; 130(12):2801-11. DOI: 10.1002/ijc.26277. View

2.
Lamph W, Wamsley P, Sassone-Corsi P, Verma I . Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature. 1988; 334(6183):629-31. DOI: 10.1038/334629a0. View

3.
Cooper S, MacGowan J, Ranger-Moore J, Young M, Colburn N, Bowden G . Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. Mol Cancer Res. 2003; 1(11):848-54. View

4.
Panopoulos A, Howell M, Fotedar R, Margolis R . Glioblastoma motility occurs in the absence of actin polymer. Mol Biol Cell. 2011; 22(13):2212-20. PMC: 3128524. DOI: 10.1091/mbc.E10-10-0849. View

5.
Han J, Jiang Y, Li Z, Kravchenko V, Ulevitch R . Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature. 1997; 386(6622):296-9. DOI: 10.1038/386296a0. View